We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$388M -$13.8M -449,943 -4%
PA
2
Perceptive Advisors
New York
$332M -$52.8M -1,723,862 -15%
ACA
3
Avoro Capital Advisors
New York
$314M -$25.3M -825,000 -8%
BlackRock
4
BlackRock
New York
$301M -$16.7M -545,165 -6%
Franklin Resources
5
Franklin Resources
California
$274M +$41.6M +1,358,111 +20%
AIM
6
ARK Investment Management
Florida
$260M +$112M +3,668,035 +87%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$228M -$10.5M -343,216 -5%
O
8
OrbiMed
New York
$219M – – –
FCM
9
Farallon Capital Management
California
$196M -$17.9M -582,500 -9%
GPP
10
Great Point Partners
Connecticut
$128M +$4.65M +151,624 +4%
NAMA
11
Nikko Asset Management Americas
New York
$116M +$23.5M +765,177 +28%
Sumitomo Mitsui Trust Group
12
Sumitomo Mitsui Trust Group
Japan
$116M +$23.3M +759,199 +28%
Bank of America
13
Bank of America
North Carolina
$106M -$887K -28,943 -0.9%
State Street
14
State Street
Massachusetts
$104M -$7.15M -233,112 -7%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$99.2M -$7.77M -253,538 -8%
Artisan Partners
16
Artisan Partners
Wisconsin
$93.2M -$4.84M -157,915 -5%
Victory Capital Management
17
Victory Capital Management
Texas
$68.4M -$5.55M -181,000 -8%
Lord, Abbett & Co
18
Lord, Abbett & Co
New Jersey
$60.8M +$2.12M +69,311 +4%
Invesco
19
Invesco
Georgia
$51.9M +$10.8M +352,995 +29%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$51.5M -$1.11M -36,161 -2%
Norges Bank
21
Norges Bank
Norway
$50.4M +$2.46M +80,375 +6%
FM
22
Frazier Management
Washington
$43.2M – – –
Citadel Advisors
23
Citadel Advisors
Florida
$42.5M -$16.9M -549,748 -30%
AllianceBernstein
24
AllianceBernstein
Tennessee
$39.9M -$4.9M -159,819 -12%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$35.3M +$625K +20,388 +2%
1
2 3 4 5

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.